Determinants of Frailty and Treatment Toxicity in Non-Small Cell Lung Cancer Patient

被引：0
|
作者：
Boucher, M. [1 ]
Mezquita, L. [2 ]
Auclin, E. [3 ]
Mons, M. [4 ]
Marghadi, J. [4 ]
Charrier, M. [4 ]
Ferrara, R. [2 ]
Planchard, D. [5 ]
Anas, G. [1 ]
Le Pechoux, C. [6 ]
Botticella, A. [7 ]
Caramella, C. [4 ]
Adam, J. [8 ]
Soria, J. [9 ]
Besse, B. [1 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] Gustave Roussy, Med Oncol Dept, Villejuif, France
[3] Hop Georges Pompidou, Paris, France
[4] Gustave Roussy, Villejuif, France
[5] Gustave Roussy, Med Oncol, Villejuif, France
[6] Gustave Roussy, Radiat Oncol, Villejuif, France
[7] Gustave Roussy, Radiotherapy, Villejuif, France
[8] Gustave Roussy Canc Campus, Dept Med Biol & Pathol, Villejuif, France
[9] Gustave Roussy Canc Campus, Drug Dev Dept, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
frailty; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-038
引用
收藏
页码：S2082 / S2083
页数：2
相关论文
共 50 条
  • [41] Developments in the treatment of non-small cell lung cancer
    Gkiozos, Ioannis
    Charpidou, Andriani
    Syrigos, Kostas
    [J]. ANTICANCER RESEARCH, 2007, 27 (4C) : 2823 - 2827
  • [42] Primary treatment of non-small cell lung cancer
    Mohr, M.
    Kessler, T.
    Krug, U.
    Hoffknecht, P.
    Schmidt, L. H.
    Wiebe, K.
    Berdel, W. E.
    Wiewrodt, R.
    [J]. ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE, 2010, 24 (02): : 97 - 104
  • [43] Capmatinib for the treatment of non-small cell lung cancer
    Vansteenkiste, Johan Filip
    Van de Kerkhove, Charlotte
    Wauters, Els
    Van Mol, Pierre
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 659 - 671
  • [44] Osimertinib for the treatment of non-small cell lung cancer
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (02) : 225 - 231
  • [45] Selumetinib for the treatment of non-small cell lung cancer
    Casaluce, Francesca
    Sgambato, Assunta
    Maione, Paolo
    Sacco, Paola Claudia
    Santabarbara, Giuseppe
    Gridelli, Cesare
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (08) : 973 - 984
  • [46] Erlotinib in the treatment of non-small cell lung cancer
    Brown, Ewan R.
    Shepherd, Frances A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 767 - 775
  • [47] Durvalumab for the treatment of non-small cell lung cancer
    Murakami, Shuji
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (12) : 1009 - 1016
  • [48] Treatment of advanced non-small cell lung cancer
    De Petris, L
    Crinò, L
    Scagliotti, GV
    Gridelli, C
    Galetta, D
    Metro, G
    Novello, S
    Maione, P
    Colucci, G
    de Marinis, F
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 36 - 41
  • [49] CERITINIB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Landi, L.
    Cappuzzo, F.
    [J]. DRUGS OF TODAY, 2014, 50 (07) : 465 - 473
  • [50] Durvalumab for the treatment of non-small cell lung cancer
    Mezquita, Laura
    Planchard, David
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (08) : 627 - 639
12345